World Courier’s Post

Dive into the exciting world of decentralized supply chains for cell and gene therapies (CGTs) with Jennifer Fenwick and Matthew Lakelin from TrakCel. They've unpacked why digital integration in your supply chain is a game-changer, and how choosing your partners wisely could be the key to success. Plus, discover why there's a shift toward decentralization in clinical trials for CGTs. Intrigued? Access their insightful full Q&A: https://lnkd.in/edqjc7E2

New on Pharma's Almanac: PPD’s Erin Schaller and Aidan Jones discuss how the growth of cell and gene therapies have produced a myriad of logistical supply chain challenges around management of complex samples, making an experienced and expert clinical research partner more critical than ever. Read the article here: https://lnkd.in/erFU493y #clinicaltrials #clinicalsupply #logistics #celltherapy #cellandgenetherapy #clinicaltriallogistics #supplychain

Next week, Nicole Tunstall will be at the Cell & Gene Therapy Pricing and Reimbursement Summit from June 25-27 in Washington, DC. Let’s connect and discuss how IMAC can help you navigate the evolving regulatory landscape and ensure the success of your commercial launches. See you there! #MarketAccess #CellandGenePricing #InflationReductionAct

A coordinated orchestration with tailored services, distribution and advanced analytics is critical to unlocking value for our CGT partners.

Ever wondered about the intricate web of logistics behind #cellandgenetherapy #clinicaltrials? From sourcing specialized equipment to navigating regulatory requirements, every step is crucial in bringing innovative treatments to patients in need. We understand the nuances of these complex supply chains and have developed an end-to-end process to support your cell and gene therapy trial every step of the way. » https://bit.ly/3V8YOOd

Have you read our recently released target product profile (TPP) guide and want to learn more about how to develop an effective TPP for successful therapy adoption? Join our webinar on the 31st of January titled 'Developing a robust target product profile (TPP) for successful therapy adoption', where Cell and Gene Therapy Catapult’s experts in #MarketAccess, #RegulatoryAffairs and #NonClinical strategy will talk through the guide, discuss the value of a TPP and how to approach building one. Register now: https://buff.ly/3RqT2nC #TargetProductProfile #CellTherapies #GeneTherapies #TherapyDevelopers

We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field. https://lnkd.in/exhRKaUz

To navigate the intricate challenges that define #CGT distribution, a forward-thinking approach is foundational to achieving commercial success. In an interview with Pharm Exec, Cencora’s Melissa Lattanzi, Vice President, Emerging Therapies, delves into crucial considerations that cell and gene therapy (CGT) developers must address to shape an effective distribution strategy ⬇️ https://ow.ly/GuyI50SEvb1

Our webinar 'Developing a robust target product profile (TPP) for successful therapy adoption' which we hosted last week is now available to view on-demand! Tune in to hear from Cell and Gene Therapy Catapult experts in market access, regulatory affairs, and non-clinical strategy talking through the resource, discussing the value of a TPP and how to approach building one as an early-stage therapy developer. Watch it here: https://buff.ly/41LxQNE #TPP #AccessStrategy #AdvancedTherapies #clinical

In the rapidly evolving world of cell and gene therapies, a collaborative supply chain is crucial for managing variability and enhancing both efficiency and safety. 🔬 In our latest blog, Chris Came explores how strategic partnerships can drive success in CGT. Don’t miss out on these valuable insights, link in comments. 👇💬 #CGT #SupplyChain #CellAndGeneTherapy #PersonalizedMedicine #SupplyChainIntegration